|Videos|December 15, 2020
Oral Semaglutide: Cardiovascular Outcomes, Safety, and Tolerability
The safety profile of oral semaglutide across the PIONEER trials was shown to be consistent with other glucagon-like peptide-1 receptor agonists (GLP-1RAs).
Click PLAY to watch the video abstract.
Click
Click
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Content
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
5 Things to Know About the Oral GLP-1 Era
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention
5
